Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis

 

Show simple item record

dc.contributor.author Van Cutsem, Gilles en_ZA
dc.contributor.author Ford, Nathan en_ZA
dc.contributor.author Hildebrand, Katherine en_ZA
dc.contributor.author Goemaere, Eric en_ZA
dc.contributor.author Mathee, Shaheed en_ZA
dc.contributor.author Abrahams, Musaed en_ZA
dc.contributor.author Coetzee, David en_ZA
dc.contributor.author Boulle, Andrew en_ZA
dc.date.accessioned 2015-11-16T04:08:01Z
dc.date.available 2015-11-16T04:08:01Z
dc.date.issued 2011 en_ZA
dc.identifier.citation Van Cutsem, G., Ford, N., Hildebrand, K., Goemaere, E., Mathee, S., Abrahams, M., ... & Boulle, A. (2011). Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One, 6(2), e14684. doi:10.1371/journal.pone.0014684 en_ZA
dc.identifier.uri http://hdl.handle.net/11427/14983
dc.identifier.uri http://dx.doi.org/10.1371/journal.pone.0014684
dc.description.abstract BACKGROUND: Loss to follow-up (LTF) challenges the reporting of antiretroviral treatment (ART) programmes, since it encompasses patients alive but lost to programme and deaths misclassified as LTF. We describe LTF before and after correction for mortality in a primary care ART programme with linkages to the national vital registration system. Methods and FINDINGS: We included 6411 patients enrolled on ART between March 2001 and June 2007. Patients LTF with available civil identification numbers were matched with the national vital registration system to ascertain vital status. Corrected mortality and true LTF were determined by weighting these patients to represent all patients LTF. We used Kaplan-Meier estimates and Cox regression to describe LTF, mortality among those LTF, and true LTF. Of 627 patients LTF, 85 (28.8%) had died within 3 months after their last clinic visits. Respective estimates of LTF before and after correction for mortality were 6.9% (95% confidence interval [CI] 6.2-7.6) and 4.3% (95% CI 3.5-5.3) at one year on ART, and 23.9% (95% CI 21.0-27.2) and 19.7% (95% CI 16.1-23.7) at 5 years. After correction for mortality, the hazard of LTF was reversed from decreasing to increasing with time on ART. Younger age, higher baseline CD4 count, pregnancy and increasing calendar year were associated with higher true LTF. Mortality of patients LTF at 1, 12 and 24 months after their last visits was respectively 23.1%, 30.9% and 43.8%; 78.0% of deaths occurred during the first 3 months after last visit and 45.0% in patients on ART for 0 to 3 months. CONCLUSIONS: Mortality of patients LTF was high and occurred early after last clinic visit, especially in patients recently started on ART. Correction for these misclassified deaths revealed that the risk of true LTF increased over time. Research targeting groups at higher risk of LTF (youth, pregnant women and patients with higher CD4 counts) is needed. en_ZA
dc.language.iso eng en_ZA
dc.publisher Public Library of Science en_ZA
dc.rights This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. en_ZA
dc.rights.uri http://creativecommons.org/licenses/by/4.0 en_ZA
dc.source PLoS One en_ZA
dc.source.uri http://journals.plos.org/plosone en_ZA
dc.subject.other Antiretroviral therapy en_ZA
dc.subject.other Death rates en_ZA
dc.subject.other Confidence intervals en_ZA
dc.title Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis en_ZA
dc.type Journal Article en_ZA
dc.rights.holder © 2011 Van Cutsem et al en_ZA
uct.type.publication Research en_ZA
uct.type.resource Article en_ZA
dc.publisher.institution University of Cape Town
dc.publisher.faculty Faculty of Health Sciences en_ZA
dc.publisher.department Institute of Infectious Disease and Molecular Medicine en_ZA
uct.type.filetype Text
uct.type.filetype Image
dc.identifier.apacitation Van Cutsem, G., Ford, N., Hildebrand, K., Goemaere, E., Mathee, S., Abrahams, M., ... Boulle, A. (2011). Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. <i>PLoS One</i>, http://hdl.handle.net/11427/14983 en_ZA
dc.identifier.chicagocitation Van Cutsem, Gilles, Nathan Ford, Katherine Hildebrand, Eric Goemaere, Shaheed Mathee, Musaed Abrahams, David Coetzee, and Andrew Boulle "Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis." <i>PLoS One</i> (2011) http://hdl.handle.net/11427/14983 en_ZA
dc.identifier.vancouvercitation Van Cutsem G, Ford N, Hildebrand K, Goemaere E, Mathee S, Abrahams M, et al. Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One. 2011; http://hdl.handle.net/11427/14983. en_ZA
dc.identifier.ris TY - Journal Article AU - Van Cutsem, Gilles AU - Ford, Nathan AU - Hildebrand, Katherine AU - Goemaere, Eric AU - Mathee, Shaheed AU - Abrahams, Musaed AU - Coetzee, David AU - Boulle, Andrew AB - BACKGROUND: Loss to follow-up (LTF) challenges the reporting of antiretroviral treatment (ART) programmes, since it encompasses patients alive but lost to programme and deaths misclassified as LTF. We describe LTF before and after correction for mortality in a primary care ART programme with linkages to the national vital registration system. Methods and FINDINGS: We included 6411 patients enrolled on ART between March 2001 and June 2007. Patients LTF with available civil identification numbers were matched with the national vital registration system to ascertain vital status. Corrected mortality and true LTF were determined by weighting these patients to represent all patients LTF. We used Kaplan-Meier estimates and Cox regression to describe LTF, mortality among those LTF, and true LTF. Of 627 patients LTF, 85 (28.8%) had died within 3 months after their last clinic visits. Respective estimates of LTF before and after correction for mortality were 6.9% (95% confidence interval [CI] 6.2-7.6) and 4.3% (95% CI 3.5-5.3) at one year on ART, and 23.9% (95% CI 21.0-27.2) and 19.7% (95% CI 16.1-23.7) at 5 years. After correction for mortality, the hazard of LTF was reversed from decreasing to increasing with time on ART. Younger age, higher baseline CD4 count, pregnancy and increasing calendar year were associated with higher true LTF. Mortality of patients LTF at 1, 12 and 24 months after their last visits was respectively 23.1%, 30.9% and 43.8%; 78.0% of deaths occurred during the first 3 months after last visit and 45.0% in patients on ART for 0 to 3 months. CONCLUSIONS: Mortality of patients LTF was high and occurred early after last clinic visit, especially in patients recently started on ART. Correction for these misclassified deaths revealed that the risk of true LTF increased over time. Research targeting groups at higher risk of LTF (youth, pregnant women and patients with higher CD4 counts) is needed. DA - 2011 DB - OpenUCT DO - 10.1371/journal.pone.0014684 DP - University of Cape Town J1 - PLoS One LK - https://open.uct.ac.za PB - University of Cape Town PY - 2011 T1 - Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis TI - Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis UR - http://hdl.handle.net/11427/14983 ER - en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Except where otherwise noted, this item's license is described as This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.